Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 2, 2021

Entos to commence Phase II Covid-19 vaccine trial in South Africa

The SAHPRA approval is based on positive data from the Phase I trial of the Covigenix VAX-001 vaccine.

Entos Pharmaceuticals has obtained approval from the South African Health Products Regulatory Authority (SAHPRA) to commence a Phase II clinical trial of its Covid-19 vaccine candidate, Covigenix VAX-001, in the country.

Made using the Entos’ Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, the deoxyribonucleic acid (DNA) vaccine encodes the SARS-CoV-2 Spike protein.

It also includes two genetic adjuvants to induce the innate and adaptive immune systems, offering efficient and long-term protection from Covid-19.

The Fusogenix platform leverages a new mechanism of action to carry molecules directly into the cytosol of intended cells in an intact and unaltered manner.

The latest approval is based on positive Phase I data, which showed that Covigenix VAX-001 met all the safety goals without any serious adverse events noted in the trial.

Furthermore, the Fusogenix platform was found to be safe and well-tolerated for the intracellular delivery of DNA in the trial.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

The platform also showed the potential to induce positive immunological outcomes at reduced dose levels of the vaccine.

The placebo-controlled, randomised, observer-blind Phase II trial will assess the safety, tolerability and immunogenicity of intramuscular doses of the vaccine in single-dose and double-dose groups.

To be carried out at various centres in South Africa, the trial will enrol healthy adults aged 18 years or above.

Entos Pharmaceuticals CEO John Lewis said: “We are excited to be moving forward with testing our Covid-19 DNA vaccine candidate in Phase II clinical trials after promising Phase I results.

“Reaching this important milestone gets us one step closer towards helping end this pandemic by providing a potentially effective and safe fridge-stable, single-dose vaccine against Covid-19 to under-vaccinated regions of the world.”

Due to the increased stability of DNA, VAX-001 could be stable for more than one year at standard refrigerated temperatures.

This makes the vaccine a more cost-efficient option for storing, transporting and deployment globally, the company noted.

Covigenix VAX-001 showed potent immunogenicity, offering protection from Covid-19 infection in animal models in preclinical studies.

In April, Aegis Life initiated dosing of the first participants in a Phase I/II clinical trial with Entos’ Covigenix VAX-001 to induce immunity against SARS-CoV-2.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU